Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02866981 · ClinicalTrials.gov registry record · Phase 2
Observation for Patients With Asymptomatic CNS Metastatic Disease
A Phase 2 study, sponsored by The Cooper Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02866981: Completed Phase 2 study, sponsored by The Cooper Health System.
NCT02866981 is a Phase 2 study that has completed, run by The Cooper Health System. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02866981, a Phase 2 study, has completed, sponsored by The Cooper Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this registry is to determine if select patients with CNS metastatic disease can be safely observed rather than treated. The investigators hypothesize that there is a subset of patients with small asymptomatic CNS mets that do not require treatment, these patients can simply be observed and will not have CNS progression.
Primary Outcome
Kaplan-Meier survival analyses
Interventions
- OTHER Observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-12-01 |
| Phase | Phase 2 |
What the finished NCT02866981 record still lists
NCT02866981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Observation is the first listed.
NCT02866981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02866981 about?
NCT02866981 is a clinical study titled "Observation for Patients With Asymptomatic CNS Metastatic Disease". The purpose of this registry is to determine if select patients with CNS metastatic disease can be safely observed rather than treated. The investigators hypothesize that there is a subset of patients with small asymptomatic CNS mets that do not require treatment, these patients can simply be observ...
What is the current status of trial NCT02866981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2014-02. Estimated completion is 2017-12-01.
What interventions are being tested in trial NCT02866981?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT02866981?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02866981's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia